Highlight
– Henagliflozin treatment significantly increased telomere length, a key biomarker of cellular aging, in patients with type 2 diabetes.
– The drug elevated insulin-like growth factor-binding protein-3 (IGFBP-3) and β-hydroxybutyrate levels, indicative of beneficial metabolic modulation.
– Enhanced cytotoxic T lymphocyte (CTL) function was evidenced by increased granzyme B expression, suggesting improved immune surveillance.
– Metabolomic profiling revealed upregulation of thiamine levels and metabolism, pointing to multiple pathways of potential anti-aging effects.
